- Conditions
- Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
- Interventions
- Exparel (Bupivacaine Liposome), Saline
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 22, 2026, 12:13 AM EDT